Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Nabla Bio Scores $26M Series A Financing Round

2024-05-14
CAMBRIDGE, MA, Nabla Bio, pioneers in generative protein design, today announced the close of a $26 million Series A financing.
The round was led by Radical Ventures with participation from all existing investors, and strategic collaborations with AstraZeneca, Bristol Myers Squibb Company and Takeda, worth more than $550 million in upfront and milestone payments, plus royalties.

Nabla Bio develops AI and wet-lab technologies that enable the rational design of developable, selective, and functional drugs against previously undruggable targets. Since launching in 2021 the company has raised $37 million with the backing of leading investors, including Radical Ventures, Khosla Ventures and Zetta Venture Partners. The company is headquartered in Cambridge, Mass. and continues to hire top machine learning and synthetic biology talent.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors